Antifungals market seen reaching $44.96 billion by 2030

By AI, Created 10:28 AM UTC, May 20, 2026, /AGP/ – The global antifungals market is projected to rise from $29.6 billion in 2025 to $44.96 billion by 2030, driven by more fungal infections, antifungal resistance and expanded healthcare access. North America led the market in 2025, while the Middle East is expected to post the fastest growth.

Why it matters: - Fungal infections are becoming more common worldwide, increasing demand for treatments across hospitals, clinics and outpatient care. - The market forecast points to sustained growth in a pharmaceutical category tied to infection control, immunosuppressed patients and broader access to diagnosis and care. - Rising antifungal resistance adds pressure for safer and more effective treatment options.

What happened: - The Business Research Company projected the antifungals market will grow from $29.6 billion in 2025 to $31.98 billion in 2026. - The firm said the market is on track to reach $44.96 billion by 2030. - The forecast implies an 8.1% compound annual growth rate in the near term and 8.9% through 2030. - The report was released May 8, 2026, from London. - The company offered a free sample of the antifungals market report and a full market report.

The details: - Antifungal drugs, also called antimycotic agents, are used to identify and eliminate fungal pathogens. - The drugs treat and help prevent infections ranging from athlete’s foot, ringworm and candidiasis to cryptococcal meningitis. - These medicines work by targeting fungal cell walls, membranes or essential enzymatic pathways. - The report cited increasing hospital-acquired infections, widespread use of azole antifungals, a growing immunosuppressed population and the global burden of fungal disease as drivers of recent growth. - The report also pointed to rising systemic fungal infections, concerns over antifungal resistance, demand for safer treatments, expansion of hospital care facilities and higher diagnosis rates as future growth factors. - Fungal infections affect the skin, nails, lungs and mucous membranes. - Rising temperatures and climate change have created conditions that help fungi thrive and spread. - The UK Health Security Agency reported a 4% increase in bloodstream infections caused by yeast in 2024 compared with 2023, rising from 2,170 to 2,247 cases. - Healthcare infrastructure improvements are also supporting market growth through expanded facilities, systems and resources for care. - Baker McKenzie said in May 2024 that the Australian government committed 1.82 billion Australian dollars, about $1.3 billion, to strengthen Medicare, following a prior investment of 3.95 billion Australian dollars. - Baker McKenzie also noted 91.48 million dollars was allocated for medical research and services addressing chronic conditions such as skin cancer and diabetes.

Between the lines: - The forecast suggests antifungal demand is being shaped by both epidemiology and health-system capacity, not just drug innovation. - The emphasis on resistance and safer treatments signals a market that may favor newer therapies and broader diagnostic coverage. - Climate-linked spread of fungi could keep pressure on health systems even if treatment access improves. - North America held the largest share of the antifungals market in 2025, while the Middle East is expected to be the fastest-growing region.

What’s next: - The Business Research Company expects growth to continue through 2030 as diagnosis rates rise and hospital networks expand. - The report said market momentum will likely track infection trends, access to care and the pace of antifungal resistance. - The company listed additional related reports on fungicides and candidiasis therapeutics.